Antibiotic resistance: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(6 intermediate revisions by 3 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
'''Antibiotic resistance''' is the ability of a [[micro-organism]] to withstand the effects of an [[antibiotic]]. It is a specific type of [[drug resistance]]. Antibiotic resistance evolves naturally via [[natural selection]] through random [[mutation]], but it could also be engineered.  Once such a [[gene]] is generated, bacteria can then transfer the genetic information in a horizontal fashion (between individuals) by [[plasmid]] exchange.  If a bacterium carries several resistance genes, it is called '''multiresistant''' or, informally, a '''superbug'''.
'''Antibiotic resistance''' is the ability of a [[micro-organism]] to withstand the effects of an [[antibiotic]]. It is a specific type of [[drug resistance]]. Antibiotic resistance evolves naturally via [[natural selection]] through random [[mutation]], but it could also be engineered.  Once such a [[gene]] is generated, bacteria can then transfer the genetic information in a horizontal fashion (between individuals) by [[plasmid]] exchange.  If a bacterium carries several resistance genes, it is called multiresistant or, informally, a superbug. Antibiotic resistance can also be introduced artificially into a micro-organism through [[transformation (genetics)|transformation]] protocols.  This can be a useful way of implanting artificial genes into the micro-organism.
<!--More detail needed-->


Antibiotic resistance can also be introduced artificially into a micro-organism through [[transformation (genetics)|transformation]] protocols.  This can be a useful way of implanting artificial genes into the micro-organism.
<!--More detail needed-->
==Causes==
==Causes==
[[Image:Antibiotic resistance.svg|thumb|size=180px|left|Schematic representation of how antibiotic resistance evolves via natural selection. The top section represents a population of bacteria before exposure to an antibiotic. The middle section shows the population directly after exposure, the phase in which selection took place. The last section shows the distribution of resistance in a new generation of bacteria. The legend indicates the resistance levels of individuals.]]
[[Image:Antibiotic resistance.svg|thumb|left|Schematic representation of how antibiotic resistance evolves via natural selection. The top section represents a population of bacteria before exposure to an antibiotic. The middle section shows the population directly after exposure, the phase in which selection took place. The last section shows the distribution of resistance in a new generation of bacteria. The legend indicates the resistance levels of individuals.]]


Antibiotic resistance is a consequence of [[evolution]] via [[natural selection]].  The antibiotic action is an environmental pressure; those bacteria which have a mutation allowing them to survive will live on to reproduce.  They will then pass this trait to their offspring, which will be a fully resistant generation. If let untreated, the victim will quickly die.
Antibiotic resistance is a consequence of [[evolution]] via [[natural selection]].  The antibiotic action is an environmental pressure; those bacteria which have a mutation allowing them to survive will live on to reproduce.  They will then pass this trait to their offspring, which will be a fully resistant generation. If let untreated, the victim will quickly die.


Researchers have recently demonstrated the bacterial protein [[LexA]] may play a key role in the acquisition of bacterial mutations<ref>[http://biology.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pbio.0030176#JOURNAL-PBIO-0030176-B30 Inhibition of Mutation and Combating the Evolution of Antibiotic Resistance'' Ryan T. Cirz, Jodie K. Chin, David R. Andes, Valérie de Crécy-Lagard, William A. Craig, Floyd E. Romesberg Plos Biology Volume 3, Issue 6, June 2005.]</ref>.
Researchers have recently demonstrated the bacterial protein [[LexA]] may play a key role in the acquisition of bacterial mutations.


Studies have demonstrated that patterns of antibiotic usage greatly affect the number of resistant organisms which develop. Overuse of [[broad-spectrum antibiotic]]s, such as second- and third-generation [[cephalosporin]]s, greatly hastens the development of methicillin resistance. Other factors contributing towards resistance include incorrect diagnosis, unnecessary prescriptions, improper use of antibiotics by patients, and the use of antibiotics as livestock food additives for growth promotion.
Studies have demonstrated that patterns of antibiotic usage greatly affect the number of resistant organisms which develop. Overuse of [[broad-spectrum antibiotic]]s, such as second- and third-generation [[cephalosporin]]s, greatly hastens the development of methicillin resistance. Other factors contributing towards resistance include incorrect diagnosis, unnecessary prescriptions, improper use of antibiotics by patients, and the use of antibiotics as livestock food additives for growth promotion.


Factors that affect how physicians prescribe antibiotics include:
Factors that affect how physicians prescribe antibiotics include:
* "Physicians were more likely to prescribe antibiotics to patients who they believed expected them, although they (the physicians) correctly identified only about 1 in 4 of those patients".<ref name="pmid17467120">{{cite journal |author=Ong S,  Nakase J, Moran GJ, Karras DJ, Kuehnert MJ, Talan DA |title=Antibiotic  use for emergency department patients with upper respiratory  infections: prescribing practices, patient expectations, and patient  satisfaction |journal=Annals of emergency medicine |volume=50  |issue=3  |pages=213-20  |year=2007  |pmid=17467120  |doi=10.1016/j.annemergmed.2007.03.026}}</ref>
* "Physicians were more likely to prescribe antibiotics to patients who they believed expected them, although they (the physicians) correctly identified only about 1 in 4 of those patients".
* Physicians may be more likely to prescribe antibiotics when the physicians are tired during clinical care.<ref name="pmid25286067">{{cite journal| author=Linder JA, Doctor JN, Friedberg MW, Reyes Nieva H, Birks C, Meeker D et al.| title=Time of Day and the Decision to Prescribe Antibiotics. | journal=JAMA Intern Med | year= 2014 | volume=  | issue=  | pages=  | pmid=25286067 | doi=10.1001/jamainternmed.2014.5225 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25286067  }} </ref>
* Physicians may be more likely to prescribe antibiotics when the physicians are tired during clinical care.
* The use of antibiotics  varies among countries.<ref name="pmid19549995">{{cite journal |author=Butler CC, Hood K,  Verheij T, ''et  al.'' |title=Variation in  antibiotic prescribing and its impact on recovery in patients with acute  cough in primary care: prospective study in 13 countries |journal=BMJ  |volume=338 |issue= |pages=b2242 |year=2009 |pmid=19549995 |doi= |url=http://bmj.com/cgi/pmidlookup?view=long&pmid=19549995  |issn=}}</ref>
* The use of antibiotics  varies among countries.


==Mechanisms==
==Mechanisms==
Line 36: Line 35:
A ''new'' class of antibiotics, [[Linezolid|oxazolidinone]]s, became available in the 1990s, and the first commercially available oxazolidinone, [[linezolid]], is comparable to vancomycin in effectiveness against MRSA. Linezolid-resistance in ''[[Staphylococcus aureus]]'' was reported in 2003.
A ''new'' class of antibiotics, [[Linezolid|oxazolidinone]]s, became available in the 1990s, and the first commercially available oxazolidinone, [[linezolid]], is comparable to vancomycin in effectiveness against MRSA. Linezolid-resistance in ''[[Staphylococcus aureus]]'' was reported in 2003.


CA-MRSA has now emerged as an epidemic that is responsible for rapidly progressive, fatal diseases including necrotizing pneumonia, severe sepsis and necrotizing fasciitis.<ref>[Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. PMID 17146447 ]</ref> Methicillin-resistant ''[[Staphylococcus aureus]]'' ([[MRSA]]) is the most frequently identified antimicrobial drug-resistant pathogen in US hospitals. The [[epidemiology]] of infections caused by MRSA is rapidly changing. In the past 10 years, infections caused by this organism have emerged in the community. The 2 MRSA clones in the United States most closely associated with community outbreaks, USA400 (MW2 strain, ST1 lineage) and USA300, often contain [[Panton-Valentine leukocidin]] (PVL) genes and, more frequently, have been associated with skin and soft tissue infections. Outbreaks of community-associated (CA)-MRSA infections have been reported in correctional facilities, among athletic teams, among military recruits, in newborn nurseries, and among active [[Homosexuality|homosexual]] men. CA-MRSA infections now appear to be endemic in many urban regions and cause most CA-S. aureus infections.<ref>[http://www.cdc.gov/eid/content/13/2/236.htm?s_cid=eid236_e Community-associated Methicillin-resistant Staphylococcus aureus Isolates Causing Healthcare-associated Infections]</ref>
CA-MRSA has now emerged as an epidemic that is responsible for rapidly progressive, fatal diseases including necrotizing pneumonia, severe sepsis and necrotizing fasciitis. Methicillin-resistant ''[[Staphylococcus aureus]]'' ([[MRSA]]) is the most frequently identified antimicrobial drug-resistant pathogen in US hospitals. The [[epidemiology]] of infections caused by MRSA is rapidly changing. In the past 10 years, infections caused by this organism have emerged in the community. The 2 MRSA clones in the United States most closely associated with community outbreaks, USA400 (MW2 strain, ST1 lineage) and USA300, often contain [[Panton-Valentine leukocidin]] (PVL) genes and, more frequently, have been associated with skin and soft tissue infections. Outbreaks of community-associated (CA)-MRSA infections have been reported in correctional facilities, among athletic teams, among military recruits, in newborn nurseries, and among active [[Homosexuality|homosexual]] men. CA-MRSA infections now appear to be endemic in many urban regions and cause most CA-S. aureus infections.


''[[Enterococcus|Enterococcus faecium]]'' is another superbug found in hospitals. [[Penicillin-Resistant Enterococcus]] was seen in 1983, [[Vancomycin-Resistant Enterococcus]] (VRE) in 1987, and [[Linezolid-Resistant Enterococcus]] (LRE) in the late 1990s.
''[[Enterococcus|Enterococcus faecium]]'' is another superbug found in hospitals. [[Penicillin-Resistant Enterococcus]] was seen in 1983, [[Vancomycin-Resistant Enterococcus]] (VRE) in 1987, and [[Linezolid-Resistant Enterococcus]] (LRE) in the late 1990s.


''[[Streptococcus pyogenes]]'' (Group A Streptococcus: GAS) infections can usually be treated with many different antibiotics. Early treatment may reduce the risk of death from invasive group A streptococcal disease. However, even the best medical care does not prevent death in every case. For those with very severe illness, supportive care in an intensive care unit may be needed. For persons with necrotizing fasciitis, surgery often is needed to remove damaged tissue.<ref>[http://www.cdc.gov/ncidod/dbmd/diseaseinfo/groupastreptococcal_g.htm Group A Streptococcal (GAS) Disease]</ref> Strains of ''S. pyogenes'' resistant to [[macrolide]] antibiotics have emerged, however all strains remain uniformly sensitive to [[penicillin]].<ref>[http://www.cdc.gov/ncidod/eid/vol10no3/03-0252.htm Antibiotic Selection Pressure and Resistance in Streptococcus spp.]</ref>
''[[Streptococcus pyogenes]]'' (Group A Streptococcus: GAS) infections can usually be treated with many different antibiotics. Early treatment may reduce the risk of death from invasive group A streptococcal disease. However, even the best medical care does not prevent death in every case. For those with very severe illness, supportive care in an intensive care unit may be needed. For persons with necrotizing fasciitis, surgery often is needed to remove damaged tissue.  Strains of ''S. pyogenes'' resistant to [[macrolide]] antibiotics have emerged, however all strains remain uniformly sensitive to [[penicillin]].


Resistance of ''[[Streptococcus pneumoniae]]'' to penicillin and other beta-lactams is increasing worldwide. The major mechanism of resistance involves the introduction of mutations in genes encoding penicillin-binding proteins. Selective pressure is thought to play an important role, and use of beta-lactam antibiotics has been implicated as a risk factor for infection and colonization. Streptococcus pneumoniae is responsible for [[pneumonia]], [[bacteremia]], [[otitis media]], [[meningitis]], [[sinusitis]], [[peritonitis]] and [[arthritis]].<ref>[http://www.cdc.gov/ncidod/eid/vol6no5/diekama.htm Antimicrobial-Drug Use and Changes in Resistance in Streptococcus pneumoniae]</ref>
Resistance of ''[[Streptococcus pneumoniae]]'' to penicillin and other beta-lactams is increasing worldwide. The major mechanism of resistance involves the introduction of mutations in genes encoding penicillin-binding proteins. Selective pressure is thought to play an important role, and use of beta-lactam antibiotics has been implicated as a risk factor for infection and colonization. Streptococcus pneumoniae is responsible for [[pneumonia]], [[bacteremia]], [[otitis media]], [[meningitis]], [[sinusitis]], [[peritonitis]] and [[arthritis]].


''Proteus'' can cause urinary tract infections and hospital-acquired infections. ''Proteus'' is unique, however, because it is highly motile and does not form regular colonies. Instead, ''Proteus'' forms what are known as "swarming colonies" when plated on non-inhibitory media. The most important member of this genus is considered to be ''[[Proteus mirabilis]]'', a cause of wound and urinary tract infections. Fortunately, most strains of ''Proteus mirabilis'' are sensitive to ampicillin and cephalosporins. Unlike its relative, ''[[Proteus vulgaris]]'' is not sensitive to these antibiotics. However, this organism is isolated less often in the laboratory and usually only targets immunosuppressed individuals. ''Proteus vulgaris'' occurs naturally in the intestines of humans and a wide variety of animals; also manure, soil and polluted waters. More than 80% of human [[urinary tract infections]] (UTI) are due to the bacterium ''[[Escherichia coli]]'' but urinary infections due to ''Proteus mirabilis'' are also well documented. ''Proteus mirabilis'' once attached to urinary tract, infects the kidney more commonly than ''E. coli''. ''Proteus mirabilis'' belongs to family Enterobacteriaceae and is a gram-negative motile swarmer bacterium. ''Proteus mirabili''s are often found as free-living organisms in soil and water but they are also parasitic in the upper urinary tract of human beings.
''Proteus'' can cause urinary tract infections and hospital-acquired infections. ''Proteus'' is unique, however, because it is highly motile and does not form regular colonies. Instead, ''Proteus'' forms what are known as "swarming colonies" when plated on non-inhibitory media. The most important member of this genus is considered to be ''[[Proteus mirabilis]]'', a cause of wound and urinary tract infections. Fortunately, most strains of ''Proteus mirabilis'' are sensitive to ampicillin and cephalosporins. Unlike its relative, ''[[Proteus vulgaris]]'' is not sensitive to these antibiotics. However, this organism is isolated less often in the laboratory and usually only targets immunosuppressed individuals. ''Proteus vulgaris'' occurs naturally in the intestines of humans and a wide variety of animals; also manure, soil and polluted waters. More than 80% of human [[urinary tract infections]] (UTI) are due to the bacterium ''[[Escherichia coli]]'' but urinary infections due to ''Proteus mirabilis'' are also well documented. ''Proteus mirabilis'' once attached to urinary tract, infects the kidney more commonly than ''E. coli''. ''Proteus mirabilis'' belongs to family Enterobacteriaceae and is a gram-negative motile swarmer bacterium. ''Proteus mirabili''s are often found as free-living organisms in soil and water but they are also parasitic in the upper urinary tract of human beings.
Line 48: Line 47:
Penicillin-resistant [[pneumonia]] caused by ''[[Streptococcus pneumoniae]]'' (commonly known as ''pneumococcus''), was first detected in 1967, as was penicillin-resistant [[gonorrhea]]. Resistance to penicillin substitutes is also known as beyond ''S. aureus''. By 1993 ''[[Escherichia coli]]'' was resistant to five [[quinolones|fluoroquinolone]] variants. ''[[tuberculosis|Mycobacterium tuberculosis]]'' is commonly resistant to [[isoniazid]] and [[rifampin]] and sometimes universally resistant to the common treatments. Other pathogens showing some resistance include ''[[Salmonella]]'', ''[[Campylobacter]]'', and ''[[Streptococci]]''.
Penicillin-resistant [[pneumonia]] caused by ''[[Streptococcus pneumoniae]]'' (commonly known as ''pneumococcus''), was first detected in 1967, as was penicillin-resistant [[gonorrhea]]. Resistance to penicillin substitutes is also known as beyond ''S. aureus''. By 1993 ''[[Escherichia coli]]'' was resistant to five [[quinolones|fluoroquinolone]] variants. ''[[tuberculosis|Mycobacterium tuberculosis]]'' is commonly resistant to [[isoniazid]] and [[rifampin]] and sometimes universally resistant to the common treatments. Other pathogens showing some resistance include ''[[Salmonella]]'', ''[[Campylobacter]]'', and ''[[Streptococci]]''.


In November 2004, the [[Centers for Disease Control and Prevention]] (CDC) reported an increasing number of ''[[Acinetobacter baumannii]]'' bloodstream infections in patients at military medical facilities in which service members injured in the [[Iraq]]/[[Kuwait]] region during [[Iraq war|Operation Iraqi Freedom]] and in [[Afghanistan]] during [[Operation Enduring Freedom]] were treated. Most of these showed [[multidrug resistance]] (MRAB), with a few isolates resistant to all drugs tested.<ref>[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5345a1.htm cdc.gov]</ref>
In November 2004, the [[Centers for Disease Control and Prevention]] (CDC) reported an increasing number of ''[[Acinetobacter baumannii]]'' bloodstream infections in patients at military medical facilities in which service members injured in the [[Iraq]]/[[Kuwait]] region during [[Iraq war|Operation Iraqi Freedom]] and in [[Afghanistan]] during [[Operation Enduring Freedom]] were treated. Most of these showed [[multidrug resistance]] (MRAB), with a few isolates resistant to all drugs tested.


===''Pseudomonas''===
===''Pseudomonas''===
''[[Pseudomonas aeruginosa]]'' is a highly relevant [[opportunistic pathogen]]. One of the most worrisome characteristics of ''[[P. aeruginosa]]'' consists in its low [[antibiotic]] susceptibility. This low susceptibility is attributable to a concerted action of [[multidrug efflux pump]]s with chromosomally-encoded antibiotic resistance genes and the low permeability of the bacterial cellular envelopes. Besides intrinsic resistance, ''P. aeruginosa'' easily develop acquired resistance either by [[mutation]] in chromosomally-encoded genes, either by the horizontal gene transfer of antibiotic resistance determinants. Development of [[multidrug resistance]] by ''P. aeruginosa'' isolates requires several different genetic events that include acquisition of different mutations and/or horizontal transfer of [[antibiotic resistance gene]]s. Hypermutation favours the selection of mutation-driven antibiotic resistance in ''P. aeruginosa'' strains producing chronic infections, whereas the clustering of several different antibiotic resistance genes in [[integron]]s favours the concerted acquisition of antibiotic resistance determinants. Some recent studies have shown that phenotypic resistance associated to [[biofilm]] formation or to the emergence of small-colony-variants may be important in the response of ''P. aeruginosa'' populations to [[antibiotic]]s treatment.<ref name=Cornelis>{{cite book | author = Cornelis P (editor). | title = Pseudomonas: Genomics and Molecular Biology | edition = 1st ed. | publisher = Caister Academic Press | year = 2008 | url=http://www.horizonpress.com/pseudo | id = [http://www.horizonpress.com/pseudo ISBN 978-1-904455-19-6 ]}}</ref>
''[[Pseudomonas aeruginosa]]'' is a highly relevant [[opportunistic pathogen]]. One of the most worrisome characteristics of ''[[P. aeruginosa]]'' consists in its low [[antibiotic]] susceptibility. This low susceptibility is attributable to a concerted action of [[multidrug efflux pump]]s with chromosomally-encoded antibiotic resistance genes and the low permeability of the bacterial cellular envelopes. Besides intrinsic resistance, ''P. aeruginosa'' easily develop acquired resistance either by [[mutation]] in chromosomally-encoded genes, either by the horizontal gene transfer of antibiotic resistance determinants. Development of [[multidrug resistance]] by ''P. aeruginosa'' isolates requires several different genetic events that include acquisition of different mutations and/or horizontal transfer of [[antibiotic resistance gene]]s. Hypermutation favours the selection of mutation-driven antibiotic resistance in ''P. aeruginosa'' strains producing chronic infections, whereas the clustering of several different antibiotic resistance genes in [[integron]]s favours the concerted acquisition of antibiotic resistance determinants. Some recent studies have shown that phenotypic resistance associated to [[biofilm]] formation or to the emergence of small-colony-variants may be important in the response of ''P. aeruginosa'' populations to [[antibiotic]]s treatment.


==Role of animals==
==Role of animals==
[[Methicillin Resistant Staphylococcus Aureus|MRSA]] is acknowledged to be a human [[commensal]] and [[pathogen]].  MRSA has been found in cats, dogs and horses, where it can cause the same problems as it does in humans.  Owners can transfer the organism to their pets and vice-versa, and MRSA in animals is generally believed to be derived from humans.
[[Methicillin Resistant Staphylococcus Aureus|MRSA]] is acknowledged to be a human [[commensal]] and [[pathogen]].  MRSA has been found in cats, dogs and horses, where it can cause the same problems as it does in humans.  Owners can transfer the organism to their pets and vice-versa, and MRSA in animals is generally believed to be derived from humans.


Currently, it is estimated that greater than 55% of the antibiotics used in the US are given to food animals (e.g. chickens, pigs and cattle) in the absence of disease. Antibiotic use in food animal production has been associated with the emergence of antibiotic-resistant strains of bacteria including [[Salmonella]], [[Campylobacter]], [[Escherichia coli]] and [[Enterococcus]], among others. There is substantial evidence from the US and European Union that these resistant bacteria cause antibiotic-resistant infections in humans. The [[American Society for Microbiology]] (ASM), the [[American Public Health Association]] (APHA) and the [[American Medical Association]] (AMA) have called for substantial restrictions on antibiotic use in food animal production including an end to all non-therapeutic uses. The food animal and pharmaceutical industries have fought hard to prevent new regulations that would limit the use of antibiotics in food animal production. For example, in 2000 the [[US Food and Drug Administration]] (FDA) announced their intention to rescind approval for [[fluoroquinolone]] use in poultry production because of substantial evidence linking it to the emergence of fluoroquinolone resistant Campylobacter infections in humans. The final decision to ban fluoroquinolones from use in poultry production was not made until 5 years later because of challenges from the food animal and pharmaceutical industries.<ref>{{cite journal | author=Nelson JM, Chiller TM, Powers JH, Angulo FJ | title=Fluoroquinolone-resistant ''Campylobacter'' species and the withdrawal of fluoroquinolones from use in poultry: A public health success story | journal=Clin Infect Dis | year=2007 | volume=44 | pages=977&ndash;80 | url=http://www.journals.uchicago.edu/CID/journal/issues/v44n7/41120/41120.html }}</ref> Today, there are two federal bills (S.742 and H.R. 2562) aimed at phasing out non-therapeutic antibiotics in US food animal production. These bills are endorsed by many public health and medical organizations including the [[American Nurses Association]] (ANA), the [[American Academy of Pediatrics]] (AAP), and the [[American Public Health Association]] (APHA).
Currently, it is estimated that greater than 55% of the antibiotics used in the US are given to food animals (e.g. chickens, pigs and cattle) in the absence of disease. Antibiotic use in food animal production has been associated with the emergence of antibiotic-resistant strains of bacteria including [[Salmonella]], [[Campylobacter]], [[Escherichia coli]] and [[Enterococcus]], among others. There is substantial evidence from the US and European Union that these resistant bacteria cause antibiotic-resistant infections in humans. The [[American Society for Microbiology]] (ASM), the [[American Public Health Association]] (APHA) and the [[American Medical Association]] (AMA) have called for substantial restrictions on antibiotic use in food animal production including an end to all non-therapeutic uses. The food animal and pharmaceutical industries have fought hard to prevent new regulations that would limit the use of antibiotics in food animal production. For example, in 2000 the [[US Food and Drug Administration]] (FDA) announced their intention to rescind approval for [[fluoroquinolone]] use in poultry production because of substantial evidence linking it to the emergence of fluoroquinolone resistant Campylobacter infections in humans. The final decision to ban fluoroquinolones from use in poultry production was not made until 5 years later because of challenges from the food animal and pharmaceutical industries. Today, there are two federal bills (S.742 and H.R. 2562) aimed at phasing out non-therapeutic antibiotics in US food animal production. These bills are endorsed by many public health and medical organizations including the [[American Nurses Association]] (ANA), the [[American Academy of Pediatrics]] (AAP), and the [[American Public Health Association]] (APHA).


The illegal use of [[amantadine]] to medicate poultry in the South of China and other parts of southeast Asia means that although the [[H5N1]] ([[avian flu]]) strain that appeared in Hong Kong in 1997 was amantadine sensitive, the more recent strains have all been amantadine resistant.  This seriously reduces the treatment options available to doctors in the event of an [[influenza]] [[pandemic]].
The illegal use of [[amantadine]] to medicate poultry in the South of China and other parts of southeast Asia means that although the [[H5N1]] ([[avian flu]]) strain that appeared in Hong Kong in 1997 was amantadine sensitive, the more recent strains have all been amantadine resistant.  This seriously reduces the treatment options available to doctors in the event of an [[influenza]] [[pandemic]].
==Course duration and development of antibiotic resistance==
* Completing the [[antibiotic]] course even after resolution of symptoms is widely believed to be a must to avoid the development of [[Antibiotic resistance|antibiotic resistant strains]] by bacteria. Dr.Martin J Llewelyn, the professor of infectious diseases at Brighton and Sussex Medical School investigated this concept further.
* The roots of this belief started back in the 1940s with the development of [[antibiotics]]. Alexander Fleming himself indicated in his Nobel prize speech that insufficient penicillin for treatment of [[Streptococcus|streptococcal]] throat infection can cause other patients to get infected with resistant strains of the bacteria. But up till now, [[streptococci]] causing throat infection never developed resistance to [[penicillin]] after all these years, argues Dr.Llewelyn.
* Two mechanisms are responsible for [[antibiotic]] resistance: Targeted selection and collateral selection.
* An example of targeted selection is the resistance developed by [[Mycobacterium tuberculosis]] when an insufficient or a single [[antibiotic]] is administered. This accounts for a minority of cases of antibiotic resistance.<ref name="pmid28747365">{{cite journal |vauthors=Llewelyn MJ, Fitzpatrick JM, Darwin E, SarahTonkin-Crine, Gorton C, Paul J, Peto TEA, Yardley L, Hopkins S, Walker AS |title=The antibiotic course has had its day |journal=BMJ |volume=358 |issue= |pages=j3418 |year=2017 |pmid=28747365 |doi= |url=}}</ref>
* Collateral selection occurs when the [[bacterial flora]] present normally in the body is affected by the administered [[antibiotic]] leaving space for other resistant harmful bacterial strains.
* Collateral selection accounts for most of the cases of antibiotic resistance and it is not dependent at all on the duration of administration of the [[antibiotic]].
* The role of the duration of [[antibiotic]] administration on antibiotic resistance is clearly understudied and for most [[bacterial infections]]. The conventional course duration was not compared to a shorter course for efficacy and the development of resistant strains in most of the indications of administration of [[antibiotics]].
* [[Pyelonephritis]] was treated with [[quinolones]] for two weeks, however, trials have shown that 5-7 day course is as efficient.
* [[Antibiotic]] treatment efficacy for [[Otitis media CT or MRI|otitis media]] was not the same with shorter courses. [[Antibiotics]] gave the same clinical results with shorter and longer treatment courses and in fact, shorter courses were associated with lower recurrence rates.
* As regarding [[Hospital-acquired pneumonia|hospital acquired pneumonia]], research has shown that shorter [[antibiotic]] courses might be associated with less chance of developing resistant bacterial strains in the future.
* None of these trials have shown that antibiotic resistance was associated with the shorter courses.
* The author suggested administering antibiotics should be guided by infection [[biomarkers]] such as [[procalcitonin]] in the inpatient setting and with the symptoms of the patient in the outpatient setting. He also suggests that the message of “completing the course” should be reconsidered and changed.
* However, the topic needs further study to confirm this theory.


==Alternatives==
==Alternatives==
===Prevention===
===Prevention===
[[Hand washing|Washing hands]] properly reduces the chance of getting infected or spreading infection. Thoroughly washing or avoiding raw foods such as fruits, vegetables, raw eggs, and undercooked meat can also reduce the chance of an infection. High risk activities include: unprotected sex <ref>[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4835a1.htm Resurgent Bacterial Sexually Transmitted Disease Among Men Who Have Sex With Men]</ref>  <ref>[http://www.cdc.gov/ncidod/eid/vol10no11/04-0467.htm Barriers to Infectious Disease Care among Lesbians]</ref> <ref>[http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5511a1.htm Sexually Transmitted Diseases Treatment Guidelines, 2006]</ref>; use of equipment in a public gymnasium or on a playground; being a patient in a nursing home or hospital; being a prison inmate; visiting a barbershop; the sharing of personal products (cosmetic items, lotion, bedding, toothpaste, headphones, nail clippers, shampoo); even being overweight.
[[Hand washing|Washing hands]] properly reduces the chance of getting infected or spreading infection. Thoroughly washing or avoiding raw foods such as fruits, vegetables, raw eggs, and undercooked meat can also reduce the chance of an infection. High risk activities include: unprotected sex   ; use of equipment in a public gymnasium or on a playground; being a patient in a nursing home or hospital; being a prison inmate; visiting a barbershop; the sharing of personal products (cosmetic items, lotion, bedding, toothpaste, headphones, nail clippers, shampoo); even being overweight.


Avoiding the use of [[antibiotics]], in some situations, can also reduce the chances of infection by antibiotic-resistant bacteria. One study demonstrated that the use of [[fluoroquinolones]] is clearly associated with elevated rates of [[Clostridium difficile]] infections, which is a leading cause of [[nosocomial]] [[diarrhea]] in the United States<ref>[http://www.cdc.gov/ncidod/eid/vol9no6/02-0385.htm Fluoroquinolone Use and Clostridium difficile–associated Diarrhea]</ref> and a major cause of death, worldwide.<ref>[http://www.cdc.gov/ncidod/eid/vol4no4/frost.htm Increasing Hospitalization and Death Possibly Due to Clostridium difficile Diarrheal Disease ]</ref>
Avoiding the use of [[antibiotics]], in some situations, can also reduce the risk of infection by antibiotic-resistant bacteria. One study demonstrated that the use of [[fluoroquinolones]] is clearly associated with elevated rates of [[Clostridium difficile]] infections, which is a leading cause of [[nosocomial]] [[diarrhea]] in the United States and a major cause of death worldwide.


Interventions to reduce over-prescription of antibiotics have been systematically reviewed.<ref  name="pmid18665065">{{cite  journal |author=Ranji SR, Steinman MA, Shojania KG, Gonzales R  |title=Interventions to reduce unnecessary antibiotic prescribing: a  systematic review and quantitative analysis |journal=Med Care |volume=46  |issue=8 |pages=847–62 |year=2008 |month=August |pmid=18665065  |doi=10.1097/MLR.0b013e318178eabd |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00005650-200808000-00012  |issn=}}</ref> Multifactorial interventions aimed at both physicians and patients can reduce inappropriate prescription of antibiotics. <ref name="pmid17509729">{{cite journal |author=Metlay  JP, Camargo CA, MacKenzie T, ''et al''  |title=Cluster-randomized  trial to improve antibiotic use for adults with acute respiratory  infections treated in emergency departments |journal=Annals  of emergency medicine |volume=50 |issue=3 |pages=221-30 |year=2007 |pmid=17509729 |doi=10.1016/j.annemergmed.2007.03.022}}</ref> The delay of antibiotics administration for 48 hours while waiting on improvement of [[respiratory tract infection]]s<ref  name="pmid17636757">{{cite journal |author=Spurling G, Del Mar C, Dooley L, Foxlee R  |title=Delayed  antibiotics for respiratory infections |journal=Cochrane  database of systematic reviews (Online) |volume=  |issue=3  |pages=CD004417  |year=2007  |pmid=17636757  |doi=10.1002/14651858.CD004417.pub3}}</ref><ref name="pmid19843421">{{cite journal| author=Moore M, Little P,  Rumsby K, Kelly J, Watson L, Warner G et al.| title=Effect of antibiotic  prescribing strategies and an information leaflet on longer-term  reconsultation for acute lower respiratory tract infection. | journal=Br  J Gen Pract | year= 2009 | volume= 59 | issue= 567 | pages= 728-34 |  pmid=19843421
Interventions to reduce over-prescription of antibiotics have been systematically reviewed. Multifactorial interventions aimed at both physicians and patients can reduce inappropriate prescription of antibiotics. The delay of antibiotics administration for 48 hours while waiting on improvement of [[respiratory tract infection]]s or [[cystitis]] may reduce antibiotic usage and re-consultation; however, this strategy may reduce patient satisfaction.
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&email=badgett@uthscdsa.edu&retmode=ref&cmd=prlinks&id=19843421  | doi=10.3399/bjgp09X472601 | pmc=PMC2751917 }} </ref> or [[cystitis]]<ref name="pmid19364448">{{cite journal |author=Little P, Turner S,  Rumsby K, ''et  al'' |title=Dipsticks and  diagnostic algorithms in urinary tract infection: development and  validation, randomised trial, economic analysis, observational cohort  and qualitative study |journal=Health Technol Assess |volume=13  |issue=19 |pages=iii–iv, ix–xi, 1–73 |year=2009 |month=March  |pmid=19364448 |doi=10.3310/hta13190 |url=http://www.hta.ac.uk/execsumm/summ1319.htm |issn=}}</ref> may reduce antibiotic usage and re-consultation; however, this strategy may reduce patient satisfaction.


The rate of prescription of antibiotics may be reduced with the reassurance of clinicians that serious infection is not present through any of the following:
The rate of prescription of antibiotics may be reduced with the reassurance of clinicians that serious infection is not present. [[Health care provider]]s can be reassured when there is any of the following:
* Normal [[c-reactive  protein]] levels<ref  name="pmid19416992">{{cite  journal |author=Cals JW, Butler CC, Hopstaken RM, Hood K, Dinant  GJ |title=Effect of point of care testing for C reactive protein and  training in communication skills on antibiotic use in lower respiratory  tract infections: cluster randomised trial |journal=BMJ |volume=338  |issue= |pages=b1374 |year=2009 |pmid=19416992 |pmc=2677640 |doi= |url=http://bmj.com/cgi/pmidlookup?view=long&pmid=19416992  |issn=}}</ref>
* Normal [[c-reactive  protein]] levels
* Normal [[procalcitonin]] levels<ref  name="pmid16603606">{{cite  journal |author=Christ-Crain M, Stolz D, Bingisser R, ''et al.'' |title=Procalcitonin guidance of  antibiotic therapy in community-acquired pneumonia: a randomized trial  |journal=Am. J. Respir. Crit. Care Med. |volume=174 |issue=1  |pages=84–93 |year=2006 |month=July |pmid=16603606  |doi=10.1164/rccm.200512-1922OC |url=http://ajrccm.atsjournals.org/cgi/pmidlookup?view=long&pmid=16603606  |issn=}}</ref><ref name="pmid17218551">{{cite journal |author=Stolz D, Christ-Crain  M, Bingisser R, ''et  al.'' |title=Antibiotic treatment  of exacerbations of COPD: a randomized, controlled trial comparing  procalcitonin-guidance with standard therapy |journal=Chest |volume=131  |issue=1 |pages=9–19 |year=2007 |month=January |pmid=17218551  |doi=10.1378/chest.06-1500 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=17218551  |issn=}}</ref><ref name="pmid14987884">{{cite journal |author=Christ-Crain M,  Jaccard-Stolz D, Bingisser R, ''et al.''  |title=Effect of procalcitonin-guided treatment on antibiotic use and  outcome in lower respiratory tract infections: cluster-randomised,  single-blinded intervention trial |journal=Lancet |volume=363  |issue=9409 |pages=600–7 |year=2004 |month=February |pmid=14987884  |doi=10.1016/S0140-6736(04)15591-8 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(04)15591-8  |issn=}}</ref><ref name="pmid18852401">{{cite journal |author=Briel M, Schuetz P,  Mueller B, ''et  al'' |title=Procalcitonin-guided  antibiotic use vs a standard approach for acute respiratory tract  infections in primary care |journal=Archives of internal medicine  |volume=168 |issue=18 |pages=2000–7; discussion 2007–8 |year=2008  |month=October |pmid=18852401 |doi=10.1001/archinte.168.18.2000 |url=http://archinte.ama-assn.org/cgi/pmidlookup?view=long&pmid=18852401  |issn=}}</ref>
* Normal [[procalcitonin]] levels


===Vaccines===
===Vaccines===
Line 79: Line 96:


===Phage therapy===
===Phage therapy===
[[Phage therapy]], an approach that has been extensively researched and utilized as a therapeutic agent for over 60 years, especially in the [[Soviet Union]], is an alternative that might help with the problem of resistance. Phage Therapy was widely used in the United States until the discovery of antibiotics, in the early 1940's. Bacteriophages or "phages" are viruses that invade bacterial cells and, in the case of lytic phages, disrupt bacterial metabolism and cause the bacterium to lyse [destruct]. Phage Therapy is the therapeutic use of lytic [[bacteriophages]] to treat [[pathogenic]] bacterial infections.<ref>{{cite journal
[[Phage therapy]], an approach that has been extensively researched and utilized as a therapeutic agent for over 60 years, especially in the [[Soviet Union]], is an alternative that might help with the problem of resistance. Phage Therapy was widely used in the United States until the discovery of antibiotics, in the early 1940's. Bacteriophages or "phages" are viruses that invade bacterial cells and, in the case of lytic phages, disrupt bacterial metabolism and cause the bacterium to lyse [destruct]. Phage Therapy is the therapeutic use of lytic [[bacteriophages]] to treat [[pathogenic]] bacterial infections.
| title=Phages and their application against drug-resistant bacteria
| journal=J. Chem. Technol. Biotechnol.) 
| year=2001
| volume=76
| pages=689–699
| author=N Chanishvili, T Chanishvili, M. Tediashvili, P.A. Barrow
| url=http://cat.inist.fr/?aModele=afficheN&cpsidt=1096871 }}</ref><ref>{{cite journal
| title=The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries  caused by exposure to Sr90
| author=D. Jikia, N. Chkhaidze, E. Imedashvili, I. Mgaloblishvili, G. Tsitlanadze
| journal=Clinical & Experimental Dermatology
| year=2005
| volume=30
| pages=23
| url=http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2230.2004.01600.x?journalCode=ced }}</ref><ref>{{cite journal
| title=Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man.
| author=Weber-Dabrowska B, Mulczyk M, Gorski A.
| journal=Transplant Proc.
| year=2003
| url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12826166 }}</ref><ref>{{cite journal
| title=Bacteriophage Therapy
| author=Alexander Sulakvelidze,1,* Zemphira Alavidze,1,2 and J. Glenn Morris Jr.1
| journal=Antimicrobial Agents and Chemotherapy
| year= March 2001,
| pages=649–659
| volume=45, No. 3
| url=http://aac.asm.org/cgi/content/full/45/3/649?view=full }}</ref><ref>{{cite journal
| title=Results of Bacteriophage Treatment of Suppurative Bacterial Infections. VI. Analysis of Treatment of Suppurative Staphylococcal infections
| author=Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B, Dabrowski M.
| journal=Arch Immunol Ther Exp (Warsz).
| year=1985
|
url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2799488 }}</ref><ref>{{cite journal
| title=Results of Bacteriophage Treatment of Suppurative Bacterial Infections. V. Evaluation of the Results Obtained in Children.
| author=Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B, Dabrowski M.
| journal=Arch Immunol Ther Exp (Warsz).
| year=1985
| url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2935116 }}</ref><ref>{{cite journal
| title=Results of Bacteriophage Treatment of Suppurative Bacterial Infections. IV. Evaluation of the Results Obtained in 370 Cases.
| author=Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B, Dabrowski M.
| journal=Arch Immunol Ther Exp (Warsz).
| year=1985
| url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2935115 }}</ref><ref>{{cite journal
| title=Results of Bacteriophage Treatment of Suppurative Bacterial Infections. III. Detailed Evaluation of the Results Obtained in Further 150 Cases.
| author=Slopek S, Durlakowa I, Weber-Dabrowska B, Dabrowski M
| journal=Arch Immunol Ther Exp (Warsz).
| year=1984
| url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2935115 }}</ref><ref>{{cite journal
| title=Bacteriophage Therapy of Infected Surgical Wounds
| author=Witszka M, Strumillo B.
| journal=Pol Tyg Lek.
| year=1963 }}</ref><ref>{{cite journal
| title=Pseudomonas aeruginosa bacteriophage in treatment of P. aeruginosa infection in cystic
 
fibrosis patients,
| author=Shabalova, I. A., N. I. Karpanov, V. N. Krylov, T. O. Sharibjanova, and V. Z.
 
Akhverdijan.
| journal=Proceedings of IX International Cystic Fibrosis Congress. International Cystic
 
Fibrosis Association, Zurich, Switzerland.
| year=1995}}</ref><ref>{{cite journal
| title=The efficacy of bacteriophage preparations in treating inflammatory urologic diseases.
| author=Perepanova, T. S., O. S. Darbeeva, G. A. Kotliarova, E. M. Kondrat'eva, L. M. Maiskaia,
 
V. F. Malysheva, F. A. Baiguzina, and N. V. Grishkova. 
| journal=Urol. Nefrol.
| volume=5
| pages=14–17
| year=1995}}</ref><ref>{{cite journal
| title=Preventive effectiveness of dried polyvalent Shigella bacteriophage in organized
 
collective groups.
| author=Anpilov, L. I., and A. A. Prokudin.
| journal=Voenno-Med. Zh. (Russian)
| volume=5
| pages=39–40
| year=1984}}</ref><ref>{{cite journal
| title=Use of a new phage preparation in prophylaxis and treatment of shigellosis.
| author=Mulczyk M, Slopek S.
| journal=Acta Microbiol Acad Sci Hung
| year=1974}}</ref><ref>{{cite journal
| title=Materials on the study of bacteriophage therapy of deep forms of staphyloderma
| author=Vartapetov AIa.
| journal=Vestn Dermatol Venerol.
| year=1974}}</ref><ref>{{cite journal
| title=Use of staphylococcal bacteriophage for therapeutic and preventive purposes.
| author=Proskurov, V. A.
| journal=Zh. Mikrobiol. Epidemiol. Immunobiol.
| volume=2
| pages=104–107
| year=1970}}</ref><ref>{{cite journal
| title=Preventive value of dried dysentery bacteriophage.
| author=Babalova, E. G., K. T. Katsitadze, L. A. Sakvarelidze, N. S. Imnaishvili, T. G.
 
Sharashidze, V. A. Badashvili, G. P. Kiknadze, A. N. Meipariani, N. D. Gendzekhadze, E. V.
 
Machavariani, K. L. Gogoberidze, E. I. Gozalov, and N. G. Dekanosidze.
| journal=Zh. Mikrobiol. Epidemiol. Immunobiol.
| volume=2
| pages=143–145
| year=1968}}</ref><ref>{{cite journal
| title=Bacteriophage therapy in infective childhood asthma
| author=Wittig HJ, Raffetto JF, Bason R.
| journal=JAMA.
| year=1966}}</ref><ref>{{cite journal
| title=Bacteriophage Therapy of Infected Surgical Wounds
| author=Witoszka M, Strumillo B.
| journal=Pol Tyg Lek.
| year=1963}}</ref><ref>{{cite journal
| author=CLAEYS R.
| title=Study on a product with antibiotic action: antibiophagin
| journal=Acta Otorhinolaryngol Belg.
| year=1962}}</ref><ref>{{cite journal
| title=Progress in the Treatment of Typhoid Fever with Vi Phages
| author=Desranleau, J.M.
| journal=Canadian Journal of Public Health, Nova Scotia, Halifax, Cananda,
| year=1949}}</ref><ref>{{cite journal
| title=Treatment of typhoid fever with type-specific bacteriophage.
| author=Knouf, E. G., Ward, W. E., Reichle, P. A., Bower, A. G. and Hamilton, P. M.
| journal=J Am Med Assn
| volume=132
| pages=134–136
| year=1946}}</ref><ref>{{cite journal
| title=Dysentery Bacteriophage: Review of the Literature on its Prophylactic and Therapeutic
 
Uses in Man and in Experimental Infections in Animals.
| author=Morton, H. E. and Engely, F. B.
| journal=J Am Med Assoc
| volume=127
| pages=584–591
| year=1945}}</ref><ref>{{cite journal
| title=Treatment of wounds with bacteriophages
| author=Pokrovskaya, M. P., L. C. Kaganova, M. A. Morosenko, A. G. Bulgakova, and E. E.
 
Skatsenko.
| journal=2nd ed. State Publishing House "Medgiz,", Moscow, USSR.
| year=1942}}</ref><ref>{{cite journal
| title=Staphylococcemia 1931–1940. Five Hundred Patients
| author=Ward J. MacNeal, Frances C. Frisbee, Margaret McRae
| journal=Dept of Bacteriology, NY Postgraduate Medical School and Hospital, Columbia University, NY
| year=1940}}</ref>


Bacteriophage therapy is an important alternative to antibiotics in the current era of multidrug resistant pathogens. A review of studies that dealt with the therapeutic use of phages from 1966–1996 and few latest ongoing phage therapy projects via internet showed: phages were used topically, orally or systemically in Polish and Soviet studies. The success rate found in these studies was 80–95% with few gastrointeslinal or allergic side effects. British studies also demonstrated significant efficacy of phages against ''[[Escherichia coli]]'', ''[[Acinetobacter]]'' spp., ''[[Pseudomonas]]'' spp and ''[[Staphylococcus aureus]]''. US studies dealt with improving the bioavailability of phage. Phage therapy may prove as an important alternative to antibiotics for treating multidrug resistant pathogens.<ref>{{cite journal | title= Bacteriophage therapy: an alternative to conventional antibiotics. | author=Mathur MD, Vidhani S, Mehndiratta PL.| journal=J Assoc Physicians India | year=2003 | volume=51 | pages=593–6 | url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15266928&query_hl=13&itool=pubmed_docsum | PMID 15266928 }}</ref> <ref name=McGrath>{{cite book | author = Mc Grath S and van Sinderen D (editors). | title = Bacteriophage: Genetics and Molecular Biology  | edition = 1st ed. | publisher = Caister Academic Press | year = 2007 | url=http://www.horizonpress.com/phage | id = [http://www.horizonpress.com/phage ISBN 978-1-904455-14-1 ]}}</ref>
Bacteriophage therapy is an important alternative to antibiotics in the current era of multidrug resistant pathogens. A review of studies that dealt with the therapeutic use of phages from 1966–1996 and few latest ongoing phage therapy projects via internet showed: phages were used topically, orally or systemically in Polish and Soviet studies. The success rate found in these studies was 80–95% with few gastrointeslinal or allergic side effects. British studies also demonstrated significant efficacy of phages against ''[[Escherichia coli]]'', ''[[Acinetobacter]]'' spp., ''[[Pseudomonas]]'' spp and ''[[Staphylococcus aureus]]''. US studies dealt with improving the bioavailability of phage. Phage therapy may prove as an important alternative to antibiotics for treating multidrug resistant pathogens.  


==Development of new drugs==
==Development of new drugs==
Until recently, research and development (R&D) efforts have provided new drugs in time to treat bacteria that became resistant to older antibiotics. That is no longer the case. The potential crisis at hand is the result of a marked decrease in industry R&D, government inaction, and the increasing prevalence of resistant bacteria. Infectious disease physicians are alarmed by the prospect that effective antibiotics may not be available to treat seriously ill patients in the near future.
Until recently, research and development (R&D) efforts have provided new drugs in time to treat bacteria that became resistant to older antibiotics. That is no longer the case. The potential crisis at hand is the result of a marked decrease in industry R&D, government inaction, and the increasing prevalence of resistant bacteria. Infectious disease physicians are alarmed by the prospect that effective antibiotics may not be available to treat seriously ill patients in the near future.


The pipeline of new antibiotics is drying up. Major pharmaceutical companies are losing interest in the antibiotics market because these drugs may not be as profitable as drugs that treat chronic (long-term) conditions and lifestyle issues.<ref>[http://www.idsociety.org/Template.cfm?Section=Antimicrobials&Template=/ContentManagement/ContentDisplay.cfm&ContentID=9770 Bad Bugs, No Drugs, Executive Summary]Infectious Diseases Society of America</ref>
The pipeline of new antibiotics is drying up. Major pharmaceutical companies are losing interest in the antibiotics market because these drugs may not be as profitable as drugs that treat chronic (long-term) conditions and lifestyle issues.  


The resistance problem demands that a renewed effort be made to seek antibacterial agents effective against pathogenic bacteria resistant to current antibiotics. One of the possible strategies towards this objective is the rational localization of [[bioactive]] [[phytochemical]]s. Plants have an almost limitless ability to synthesize [[aromatic]] substances, most of which are [[phenol]]s or their oxygen-substituted derivatives such as [[tannin]]s. Most are secondary [[metabolite]]s, of which at least 12,000 have been isolated, a number estimated to be less than 10% of the total. In many cases, these substances serve as plant defense mechanisms against [[predation]] by [[micro-organism]]s, [[insect]]s, and [[herbivore]]s.  Many of  the herbs and spices used by humans to season food yield useful medicinal compounds including those having antibacterial activity<ref name=PMID15831135>Wallace RJ. (2004) "Antimicrobial properties of plant secondary metabolites.". ''Proc Nutr Soc'', jrg.63 (nr.4): pp. 621-629. '''PMID 15831135''' [http://www.ingentaconnect.com/content/cabi/pns/2004/00000063/00000004/art00016 free full-text]</ref><ref name=PMID12872531>Thuille N, Fille M, Nagl M. (2003) "Bactericidal activity of herbal extracts.". ''Int J Hyg Environ Health'', jrg.206 (nr.3): pp. 217-221. '''PMID 12872531'''</ref><ref name=PMID12410554>Singh G, Kapoor IP, Pandey SK, et al. (2002) [http://dx.doi.org/10.1002/ptr.951 "Studies on essential oils: part 10; antibacterial activity of volatile oils of some spices.".]  ''Phytother Res'', jrg.16 (nr.7): pp. 680-682. '''PMID 12410554'''</ref>
The resistance problem demands that a renewed effort be made to seek antibacterial agents effective against pathogenic bacteria resistant to current antibiotics. One of the possible strategies towards this objective is the rational localization of [[bioactive]] [[phytochemical]]s. Plants have an almost limitless ability to synthesize [[aromatic]] substances, most of which are [[phenol]]s or their oxygen-substituted derivatives such as [[tannin]]s. Most are secondary [[metabolite]]s, of which at least 12,000 have been isolated, a number estimated to be less than 10% of the total. In many cases, these substances serve as plant defense mechanisms against [[predation]] by [[micro-organism]]s, [[insect]]s, and [[herbivore]]s.  Many of  the herbs and spices used by humans to season food yield useful medicinal compounds including those having antibacterial activity


Traditional healers have long used plants to prevent or cure infectious conditions. Many of these plants have been investigated scientifically for antimicrobial activity and a large number of plant products have been shown to inhibit growth of pathogenic bacteria. A number of these agents appear to have structures and modes of action that are distinct from those of the antibiotics in current use, suggesting that cross-resistance with agents already in use may be minimal. For example the combination of [[5'-methoxyhydnocarpine]] and [[berberine]] in herbs like [[Hydrastis canadensis]] and [[Berberis vulgaris]] can block the MDR-pumps that cause multidrug resistance. This has been shown for [[Staphylococcus aureus]].<ref name=PMID10677479>Stermitz FR, Lorenz P, Tawara JN, et al. (2000) [http://dx.doi.org/10.1073/pnas.030540597 "Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor.".]  ''Proc Natl Acad Sci U S A'', jrg.97 (nr.4): pp. 1433-1437. '''PMID 10677479''' [http://www.pnas.org/cgi/pmidlookup?view=long&pmid=10677479 free full-textl]</ref>.
Traditional healers have long used plants to prevent or cure infectious conditions. Many of these plants have been investigated scientifically for antimicrobial activity and a large number of plant products have been shown to inhibit growth of pathogenic bacteria. A number of these agents appear to have structures and modes of action that are distinct from those of the antibiotics in current use, suggesting that cross-resistance with agents already in use may be minimal. For example the combination of [[5'-methoxyhydnocarpine]] and [[berberine]] in herbs like [[Hydrastis canadensis]] and [[Berberis vulgaris]] can block the MDR-pumps that cause multidrug resistance. This has been shown for [[Staphylococcus aureus]]..


==Applications==
==Applications==
Line 267: Line 143:
* [http://www.gmo-safety.eu/en/gene_transfer/44.docu.html Antibiotic-resistance genes as markers] Once necessary, now undesirable
* [http://www.gmo-safety.eu/en/gene_transfer/44.docu.html Antibiotic-resistance genes as markers] Once necessary, now undesirable
*[http://cbs5.com/health/local_story_025195614.html CBS Article on Phage Therapy and Antibiotic Resistance]
*[http://cbs5.com/health/local_story_025195614.html CBS Article on Phage Therapy and Antibiotic Resistance]
* [http://www.eu-burden.info/burden/pages/home.php BURDEN of Resistance and Disease in European Nations - An EU-Project to estimate the financial burden of antibiotic resistance in European Hospitals ]
* [http://www.eu-burden.info/burden/pages/home.php BURDEN of Resistance and Disease in European Nations - An EU-Project to estimate the financial burden of antibiotic resistance in European Hospitals]


==References==
==References==
Line 278: Line 154:
  | pages=1219&ndash;20
  | pages=1219&ndash;20
  | url=http://bmj.bmjjournals.com/cgi/content/extract/331/7527/1219?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&andorexactfulltext=and&searchid=1138116795534_11131&FIRSTINDEX=0&sortspec=relevance&volume=331&firstpage=1219&resourcetype=1 }}
  | url=http://bmj.bmjjournals.com/cgi/content/extract/331/7527/1219?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&andorexactfulltext=and&searchid=1138116795534_11131&FIRSTINDEX=0&sortspec=relevance&volume=331&firstpage=1219&resourcetype=1 }}
<references/>
<references />


[[Category:Antibiotics]]
[[Category:Antibiotics]]

Latest revision as of 18:04, 8 August 2017

WikiDoc Resources for Antibiotic resistance

Articles

Most recent articles on Antibiotic resistance

Most cited articles on Antibiotic resistance

Review articles on Antibiotic resistance

Articles on Antibiotic resistance in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Antibiotic resistance

Images of Antibiotic resistance

Photos of Antibiotic resistance

Podcasts & MP3s on Antibiotic resistance

Videos on Antibiotic resistance

Evidence Based Medicine

Cochrane Collaboration on Antibiotic resistance

Bandolier on Antibiotic resistance

TRIP on Antibiotic resistance

Clinical Trials

Ongoing Trials on Antibiotic resistance at Clinical Trials.gov

Trial results on Antibiotic resistance

Clinical Trials on Antibiotic resistance at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Antibiotic resistance

NICE Guidance on Antibiotic resistance

NHS PRODIGY Guidance

FDA on Antibiotic resistance

CDC on Antibiotic resistance

Books

Books on Antibiotic resistance

News

Antibiotic resistance in the news

Be alerted to news on Antibiotic resistance

News trends on Antibiotic resistance

Commentary

Blogs on Antibiotic resistance

Definitions

Definitions of Antibiotic resistance

Patient Resources / Community

Patient resources on Antibiotic resistance

Discussion groups on Antibiotic resistance

Patient Handouts on Antibiotic resistance

Directions to Hospitals Treating Antibiotic resistance

Risk calculators and risk factors for Antibiotic resistance

Healthcare Provider Resources

Symptoms of Antibiotic resistance

Causes & Risk Factors for Antibiotic resistance

Diagnostic studies for Antibiotic resistance

Treatment of Antibiotic resistance

Continuing Medical Education (CME)

CME Programs on Antibiotic resistance

International

Antibiotic resistance en Espanol

Antibiotic resistance en Francais

Business

Antibiotic resistance in the Marketplace

Patents on Antibiotic resistance

Experimental / Informatics

List of terms related to Antibiotic resistance

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Antibiotic resistance is the ability of a micro-organism to withstand the effects of an antibiotic. It is a specific type of drug resistance. Antibiotic resistance evolves naturally via natural selection through random mutation, but it could also be engineered. Once such a gene is generated, bacteria can then transfer the genetic information in a horizontal fashion (between individuals) by plasmid exchange. If a bacterium carries several resistance genes, it is called multiresistant or, informally, a superbug. Antibiotic resistance can also be introduced artificially into a micro-organism through transformation protocols. This can be a useful way of implanting artificial genes into the micro-organism.

Causes

Schematic representation of how antibiotic resistance evolves via natural selection. The top section represents a population of bacteria before exposure to an antibiotic. The middle section shows the population directly after exposure, the phase in which selection took place. The last section shows the distribution of resistance in a new generation of bacteria. The legend indicates the resistance levels of individuals.

Antibiotic resistance is a consequence of evolution via natural selection. The antibiotic action is an environmental pressure; those bacteria which have a mutation allowing them to survive will live on to reproduce. They will then pass this trait to their offspring, which will be a fully resistant generation. If let untreated, the victim will quickly die.

Researchers have recently demonstrated the bacterial protein LexA may play a key role in the acquisition of bacterial mutations.

Studies have demonstrated that patterns of antibiotic usage greatly affect the number of resistant organisms which develop. Overuse of broad-spectrum antibiotics, such as second- and third-generation cephalosporins, greatly hastens the development of methicillin resistance. Other factors contributing towards resistance include incorrect diagnosis, unnecessary prescriptions, improper use of antibiotics by patients, and the use of antibiotics as livestock food additives for growth promotion.

Factors that affect how physicians prescribe antibiotics include:

  • "Physicians were more likely to prescribe antibiotics to patients who they believed expected them, although they (the physicians) correctly identified only about 1 in 4 of those patients".
  • Physicians may be more likely to prescribe antibiotics when the physicians are tired during clinical care.
  • The use of antibiotics varies among countries.

Mechanisms

The four main mechanisms by which micro-organisms exhibit resistance to antimicrobials are:

  1. Drug inactivation or modification: e.g. enzymatic deactivation of Penicillin G in some penicillin-resistant bacteria through the production of β-lactamases.
  2. Alteration of target site : e.g. alteration of PBP—the binding target site of penicillins—in MRSA and other penicillin-resistant bacteria.
  3. Alteration of metabolic pathway: e.g. some sulfonamide-resistant bacteria do not require para-aminobenzoic acid (PABA), an important precursor for the synthesis of folic acid and nucleic acids in bacteria inhibited by sulfonamides. Instead, like mammalian cells, they turn to utilizing preformed folic acid.
  4. Reduced drug accumulation: by decreasing drug permeability and/or increasing active efflux on the cell surface.

Resistant pathogens

Staphylococcus aureus (colloquially known as "Staph aureus" or a Staph infection) is one of the major resistant pathogens. Found on the mucous membranes and the skin of around a third of the population, it is extremely adaptable to antibiotic pressure. It was the first bacterium in which penicillin resistance was found—in 1947, just four years after the drug started being mass-produced. Methicillin was then the antibiotic of choice, but has since been replaced by oxacillin due to significant kidney toxicity. MRSA (methicillin-resistant Staphylococcus aureus) was first detected in Britain in 1961 and is now "quite common" in hospitals. MRSA was responsible for 37% of fatal cases of blood poisoning in the UK in 1999, up from 4% in 1991. Half of all S. aureus infections in the US are resistant to penicillin, methicillin, tetracycline and erythromycin.

This left vancomycin as the only effective agent available at the time. However, VRSA (Vancomycin-resistant Staphylococcus aureus) was first identified in Japan in 1996, and has since been found in hospitals in England, France and the US. VRSA is also termed GISA (glycopeptide intermediate Staphylococcus aureus) or VISA (vancomycin insensitive Staphylococcus aureus), indicating resistance to all glycopeptide antibiotics.

A new class of antibiotics, oxazolidinones, became available in the 1990s, and the first commercially available oxazolidinone, linezolid, is comparable to vancomycin in effectiveness against MRSA. Linezolid-resistance in Staphylococcus aureus was reported in 2003.

CA-MRSA has now emerged as an epidemic that is responsible for rapidly progressive, fatal diseases including necrotizing pneumonia, severe sepsis and necrotizing fasciitis. Methicillin-resistant Staphylococcus aureus (MRSA) is the most frequently identified antimicrobial drug-resistant pathogen in US hospitals. The epidemiology of infections caused by MRSA is rapidly changing. In the past 10 years, infections caused by this organism have emerged in the community. The 2 MRSA clones in the United States most closely associated with community outbreaks, USA400 (MW2 strain, ST1 lineage) and USA300, often contain Panton-Valentine leukocidin (PVL) genes and, more frequently, have been associated with skin and soft tissue infections. Outbreaks of community-associated (CA)-MRSA infections have been reported in correctional facilities, among athletic teams, among military recruits, in newborn nurseries, and among active homosexual men. CA-MRSA infections now appear to be endemic in many urban regions and cause most CA-S. aureus infections.

Enterococcus faecium is another superbug found in hospitals. Penicillin-Resistant Enterococcus was seen in 1983, Vancomycin-Resistant Enterococcus (VRE) in 1987, and Linezolid-Resistant Enterococcus (LRE) in the late 1990s.

Streptococcus pyogenes (Group A Streptococcus: GAS) infections can usually be treated with many different antibiotics. Early treatment may reduce the risk of death from invasive group A streptococcal disease. However, even the best medical care does not prevent death in every case. For those with very severe illness, supportive care in an intensive care unit may be needed. For persons with necrotizing fasciitis, surgery often is needed to remove damaged tissue. Strains of S. pyogenes resistant to macrolide antibiotics have emerged, however all strains remain uniformly sensitive to penicillin.

Resistance of Streptococcus pneumoniae to penicillin and other beta-lactams is increasing worldwide. The major mechanism of resistance involves the introduction of mutations in genes encoding penicillin-binding proteins. Selective pressure is thought to play an important role, and use of beta-lactam antibiotics has been implicated as a risk factor for infection and colonization. Streptococcus pneumoniae is responsible for pneumonia, bacteremia, otitis media, meningitis, sinusitis, peritonitis and arthritis.

Proteus can cause urinary tract infections and hospital-acquired infections. Proteus is unique, however, because it is highly motile and does not form regular colonies. Instead, Proteus forms what are known as "swarming colonies" when plated on non-inhibitory media. The most important member of this genus is considered to be Proteus mirabilis, a cause of wound and urinary tract infections. Fortunately, most strains of Proteus mirabilis are sensitive to ampicillin and cephalosporins. Unlike its relative, Proteus vulgaris is not sensitive to these antibiotics. However, this organism is isolated less often in the laboratory and usually only targets immunosuppressed individuals. Proteus vulgaris occurs naturally in the intestines of humans and a wide variety of animals; also manure, soil and polluted waters. More than 80% of human urinary tract infections (UTI) are due to the bacterium Escherichia coli but urinary infections due to Proteus mirabilis are also well documented. Proteus mirabilis once attached to urinary tract, infects the kidney more commonly than E. coli. Proteus mirabilis belongs to family Enterobacteriaceae and is a gram-negative motile swarmer bacterium. Proteus mirabilis are often found as free-living organisms in soil and water but they are also parasitic in the upper urinary tract of human beings.

Penicillin-resistant pneumonia caused by Streptococcus pneumoniae (commonly known as pneumococcus), was first detected in 1967, as was penicillin-resistant gonorrhea. Resistance to penicillin substitutes is also known as beyond S. aureus. By 1993 Escherichia coli was resistant to five fluoroquinolone variants. Mycobacterium tuberculosis is commonly resistant to isoniazid and rifampin and sometimes universally resistant to the common treatments. Other pathogens showing some resistance include Salmonella, Campylobacter, and Streptococci.

In November 2004, the Centers for Disease Control and Prevention (CDC) reported an increasing number of Acinetobacter baumannii bloodstream infections in patients at military medical facilities in which service members injured in the Iraq/Kuwait region during Operation Iraqi Freedom and in Afghanistan during Operation Enduring Freedom were treated. Most of these showed multidrug resistance (MRAB), with a few isolates resistant to all drugs tested.

Pseudomonas

Pseudomonas aeruginosa is a highly relevant opportunistic pathogen. One of the most worrisome characteristics of P. aeruginosa consists in its low antibiotic susceptibility. This low susceptibility is attributable to a concerted action of multidrug efflux pumps with chromosomally-encoded antibiotic resistance genes and the low permeability of the bacterial cellular envelopes. Besides intrinsic resistance, P. aeruginosa easily develop acquired resistance either by mutation in chromosomally-encoded genes, either by the horizontal gene transfer of antibiotic resistance determinants. Development of multidrug resistance by P. aeruginosa isolates requires several different genetic events that include acquisition of different mutations and/or horizontal transfer of antibiotic resistance genes. Hypermutation favours the selection of mutation-driven antibiotic resistance in P. aeruginosa strains producing chronic infections, whereas the clustering of several different antibiotic resistance genes in integrons favours the concerted acquisition of antibiotic resistance determinants. Some recent studies have shown that phenotypic resistance associated to biofilm formation or to the emergence of small-colony-variants may be important in the response of P. aeruginosa populations to antibiotics treatment.

Role of animals

MRSA is acknowledged to be a human commensal and pathogen. MRSA has been found in cats, dogs and horses, where it can cause the same problems as it does in humans. Owners can transfer the organism to their pets and vice-versa, and MRSA in animals is generally believed to be derived from humans.

Currently, it is estimated that greater than 55% of the antibiotics used in the US are given to food animals (e.g. chickens, pigs and cattle) in the absence of disease. Antibiotic use in food animal production has been associated with the emergence of antibiotic-resistant strains of bacteria including Salmonella, Campylobacter, Escherichia coli and Enterococcus, among others. There is substantial evidence from the US and European Union that these resistant bacteria cause antibiotic-resistant infections in humans. The American Society for Microbiology (ASM), the American Public Health Association (APHA) and the American Medical Association (AMA) have called for substantial restrictions on antibiotic use in food animal production including an end to all non-therapeutic uses. The food animal and pharmaceutical industries have fought hard to prevent new regulations that would limit the use of antibiotics in food animal production. For example, in 2000 the US Food and Drug Administration (FDA) announced their intention to rescind approval for fluoroquinolone use in poultry production because of substantial evidence linking it to the emergence of fluoroquinolone resistant Campylobacter infections in humans. The final decision to ban fluoroquinolones from use in poultry production was not made until 5 years later because of challenges from the food animal and pharmaceutical industries. Today, there are two federal bills (S.742 and H.R. 2562) aimed at phasing out non-therapeutic antibiotics in US food animal production. These bills are endorsed by many public health and medical organizations including the American Nurses Association (ANA), the American Academy of Pediatrics (AAP), and the American Public Health Association (APHA).

The illegal use of amantadine to medicate poultry in the South of China and other parts of southeast Asia means that although the H5N1 (avian flu) strain that appeared in Hong Kong in 1997 was amantadine sensitive, the more recent strains have all been amantadine resistant. This seriously reduces the treatment options available to doctors in the event of an influenza pandemic.

Course duration and development of antibiotic resistance

  • Completing the antibiotic course even after resolution of symptoms is widely believed to be a must to avoid the development of antibiotic resistant strains by bacteria. Dr.Martin J Llewelyn, the professor of infectious diseases at Brighton and Sussex Medical School investigated this concept further.
  • The roots of this belief started back in the 1940s with the development of antibiotics. Alexander Fleming himself indicated in his Nobel prize speech that insufficient penicillin for treatment of streptococcal throat infection can cause other patients to get infected with resistant strains of the bacteria. But up till now, streptococci causing throat infection never developed resistance to penicillin after all these years, argues Dr.Llewelyn.
  • Two mechanisms are responsible for antibiotic resistance: Targeted selection and collateral selection.
  • An example of targeted selection is the resistance developed by Mycobacterium tuberculosis when an insufficient or a single antibiotic is administered. This accounts for a minority of cases of antibiotic resistance.[1]
  • Collateral selection occurs when the bacterial flora present normally in the body is affected by the administered antibiotic leaving space for other resistant harmful bacterial strains.
  • Collateral selection accounts for most of the cases of antibiotic resistance and it is not dependent at all on the duration of administration of the antibiotic.
  • The role of the duration of antibiotic administration on antibiotic resistance is clearly understudied and for most bacterial infections. The conventional course duration was not compared to a shorter course for efficacy and the development of resistant strains in most of the indications of administration of antibiotics.
  • Pyelonephritis was treated with quinolones for two weeks, however, trials have shown that 5-7 day course is as efficient.
  • Antibiotic treatment efficacy for otitis media was not the same with shorter courses. Antibiotics gave the same clinical results with shorter and longer treatment courses and in fact, shorter courses were associated with lower recurrence rates.
  • As regarding hospital acquired pneumonia, research has shown that shorter antibiotic courses might be associated with less chance of developing resistant bacterial strains in the future.
  • None of these trials have shown that antibiotic resistance was associated with the shorter courses.
  • The author suggested administering antibiotics should be guided by infection biomarkers such as procalcitonin in the inpatient setting and with the symptoms of the patient in the outpatient setting. He also suggests that the message of “completing the course” should be reconsidered and changed.
  • However, the topic needs further study to confirm this theory.

Alternatives

Prevention

Washing hands properly reduces the chance of getting infected or spreading infection. Thoroughly washing or avoiding raw foods such as fruits, vegetables, raw eggs, and undercooked meat can also reduce the chance of an infection. High risk activities include: unprotected sex  ; use of equipment in a public gymnasium or on a playground; being a patient in a nursing home or hospital; being a prison inmate; visiting a barbershop; the sharing of personal products (cosmetic items, lotion, bedding, toothpaste, headphones, nail clippers, shampoo); even being overweight.

Avoiding the use of antibiotics, in some situations, can also reduce the risk of infection by antibiotic-resistant bacteria. One study demonstrated that the use of fluoroquinolones is clearly associated with elevated rates of Clostridium difficile infections, which is a leading cause of nosocomial diarrhea in the United States and a major cause of death worldwide.

Interventions to reduce over-prescription of antibiotics have been systematically reviewed. Multifactorial interventions aimed at both physicians and patients can reduce inappropriate prescription of antibiotics. The delay of antibiotics administration for 48 hours while waiting on improvement of respiratory tract infections or cystitis may reduce antibiotic usage and re-consultation; however, this strategy may reduce patient satisfaction.

The rate of prescription of antibiotics may be reduced with the reassurance of clinicians that serious infection is not present. Health care providers can be reassured when there is any of the following:

Vaccines

Vaccines do not suffer the problem of resistance because a vaccine enhances the body's natural defenses, while an antibiotic operates separately from the body's normal defenses. Nevertheless, new strains may evolve that escape immunity induced by vaccines.

While theoretically promising, anti-staphylococcal vaccines have shown limited efficacy, because of immunological variation between Staphylococcus species, and the limited duration of effectiveness of the antibodies produced. Development and testing of more effective vaccines is under way.

Phage therapy

Phage therapy, an approach that has been extensively researched and utilized as a therapeutic agent for over 60 years, especially in the Soviet Union, is an alternative that might help with the problem of resistance. Phage Therapy was widely used in the United States until the discovery of antibiotics, in the early 1940's. Bacteriophages or "phages" are viruses that invade bacterial cells and, in the case of lytic phages, disrupt bacterial metabolism and cause the bacterium to lyse [destruct]. Phage Therapy is the therapeutic use of lytic bacteriophages to treat pathogenic bacterial infections.

Bacteriophage therapy is an important alternative to antibiotics in the current era of multidrug resistant pathogens. A review of studies that dealt with the therapeutic use of phages from 1966–1996 and few latest ongoing phage therapy projects via internet showed: phages were used topically, orally or systemically in Polish and Soviet studies. The success rate found in these studies was 80–95% with few gastrointeslinal or allergic side effects. British studies also demonstrated significant efficacy of phages against Escherichia coli, Acinetobacter spp., Pseudomonas spp and Staphylococcus aureus. US studies dealt with improving the bioavailability of phage. Phage therapy may prove as an important alternative to antibiotics for treating multidrug resistant pathogens.

Development of new drugs

Until recently, research and development (R&D) efforts have provided new drugs in time to treat bacteria that became resistant to older antibiotics. That is no longer the case. The potential crisis at hand is the result of a marked decrease in industry R&D, government inaction, and the increasing prevalence of resistant bacteria. Infectious disease physicians are alarmed by the prospect that effective antibiotics may not be available to treat seriously ill patients in the near future.

The pipeline of new antibiotics is drying up. Major pharmaceutical companies are losing interest in the antibiotics market because these drugs may not be as profitable as drugs that treat chronic (long-term) conditions and lifestyle issues.

The resistance problem demands that a renewed effort be made to seek antibacterial agents effective against pathogenic bacteria resistant to current antibiotics. One of the possible strategies towards this objective is the rational localization of bioactive phytochemicals. Plants have an almost limitless ability to synthesize aromatic substances, most of which are phenols or their oxygen-substituted derivatives such as tannins. Most are secondary metabolites, of which at least 12,000 have been isolated, a number estimated to be less than 10% of the total. In many cases, these substances serve as plant defense mechanisms against predation by micro-organisms, insects, and herbivores. Many of the herbs and spices used by humans to season food yield useful medicinal compounds including those having antibacterial activity

Traditional healers have long used plants to prevent or cure infectious conditions. Many of these plants have been investigated scientifically for antimicrobial activity and a large number of plant products have been shown to inhibit growth of pathogenic bacteria. A number of these agents appear to have structures and modes of action that are distinct from those of the antibiotics in current use, suggesting that cross-resistance with agents already in use may be minimal. For example the combination of 5'-methoxyhydnocarpine and berberine in herbs like Hydrastis canadensis and Berberis vulgaris can block the MDR-pumps that cause multidrug resistance. This has been shown for Staphylococcus aureus..

Applications

Antibiotic resistance is an important tool for genetic engineering. By constructing a plasmid which contains an antibiotic resistance gene as well as the gene being engineered or expressed, a researcher can ensure that when bacteria replicate, only the copies which carry along the plasmid survive. This ensures that the gene being manipulated passes along when the bacteria replicates.

The most commonly used antibiotics in genetic engineering are generally "older" antibiotics which have largely fallen out of use in clinical practice. These include:

Industrially the use of antibiotic resistance is disfavored since maintaining bacterial cultures would require feeding them large quantities of antibiotics. Instead, the use of auxotrophic bacterial strains (and function-replacement plasmids) is preferred.

See also

External links

References

  • Lord Soulsby of Swaffham Prior (2005). "Resistance to antimicrobials in humans and animals". Brit J Med. 331: 1219&ndash, 20.
  1. ↑ Llewelyn MJ, Fitzpatrick JM, Darwin E, SarahTonkin-Crine, Gorton C, Paul J, Peto T, Yardley L, Hopkins S, Walker AS (2017). "The antibiotic course has had its day". BMJ. 358: j3418. PMID 28747365. Vancouver style error: initials (help)


da:Antibiotikaresistens de:Antibiotikum-Resistenz nl:Resistentie tegen antibiotica sv:Antibiotikaresistens uk:Антибіотичний опір

Template:Jb1 Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Antibiotic_resistance&oldid=1337499"